Avalo Therapeutics, Inc.
AVTX
Rank in Stocks
#13436
Avalo Therapeutics, Inc. is a precision medicine company in the clinical... Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis. Furthermore, AVTX-002 is also being investigated in Phase III for its potential to treat acute respiratory distress syndrome caused by COVID-19. The company is also advancing AVTX-007, a fully human monoclonal antibody targeting IL-18, which is progressing through Phase I clinical studies for Still's disease, encompassing both adult-onset Still's disease and systemic juvenile idiopathic arthritis. Avalo's late-stage pipeline includes two products addressing rare genetic conditions, both in Phase III clinical trials: AVTX-801, a D-galactose substrate replacement therapy for phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, an L-fucose substrate replacement therapy intended for LADII, medically referred to as SLC35C1-CDG. Established in 2011, the corporation initially operated as Cerecor Inc. before rebranding as Avalo Therapeutics, Inc. in August 2021. Its main operations are situated in Rockville, Maryland.
Share Price
$7.27
Last synced: 2026-11-09
Market Cap
$389.89M
Change (1 day)
4.91%
Change (1 year)
-53.10%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Avalo Therapeutics, Inc. (AVTX)
Category
Healthcare
Operating Margin for Avalo Therapeutics, Inc. (AVTX)
Operating Margin as of November 2026 TTM: -154,844.07%
According to Avalo Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -154,844.07%. At the end of 2025 the company had an operating margin of -123,601.69%.
Operating Margin history for Avalo Therapeutics, Inc. from 2012 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -154,844.07% | 25.28% |
| 2025 | -123,601.69% | 695.60% |
| 2024 | -15,535.60% | 992.85% |
| 2023 | -1,421.57% | 585.39% |
| 2022 | -207.41% | -86.37% |
| 2021 | -1,521.56% | 0.00% |
| 2020 | 0.00% | -100.00% |
| 2019 | -239.06% | 11.44% |
| 2018 | -214.52% | -529.56% |
| 2017 | 49.94% | -103.58% |
| 2016 | -1,394.62% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | -100.00% |
| 2012 | -12,676.35% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.00% |
US
|
|
| -149.01% | -100.00% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.00% |
BE
|
|
| 29.35% | -100.00% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Avalo Therapeutics, Inc.'s operating margin
What is Avalo Therapeutics, Inc.'s operating margin?
Avalo Therapeutics, Inc.'s operating margin is -154,844.07%, as of Nov 2026.
What was Avalo Therapeutics, Inc.'s operating margin in 2025?
In 2025, Avalo Therapeutics, Inc.'s operating margin was -123,601.69%, compared with -15,535.60% in 2024.
How has Avalo Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Avalo Therapeutics, Inc.'s operating margin was highest in 2020 (0.00%) and lowest in 2025 (-123,601.69%).
How does Avalo Therapeutics, Inc.'s operating margin compare with similar companies?
Avalo Therapeutics, Inc.'s operating margin (-154,844.07%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.